XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Company Operations by Product
 6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Company Operations by Product
Company Operations by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Revenues by Product:
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Bloxiverz
 
$
5,544

 
$
13,719

 
$
13,035

 
$
27,621

Vazculep
 
11,377

 
10,154

 
24,338

 
20,334

Akovaz
 
11,875

 
20,912

 
22,092

 
46,549

Noctiva
 
289

 
—

 
955

 
—

Other
 
31

 
2,320

 
1,857

 
4,358

Total product sales
 
29,116

 
47,105

 
62,277

 
98,862

License revenue
 
114

 
(794
)
 
246

 
(44
)
Total revenues
 
$
29,230

 
$
46,311

 
$
62,523

 
$
98,818